Pharma

The proposed merger between Hucappa and Poolberg Pharma is set to create a formidable biopharma company focused on innovative cancer therapies. This report delves into the implications of the merger, the strategic goals, and the potential risks and opportunities for investors.

The latest Annual General Meeting of Sareum Holdings PLC offered shareholders a comprehensive view of the company's progress and strategic direction, with significant developments in its drug development pipeline taking centre stage. The meeting, chaired by Executive Chairman Dr Steven Parker, saw the successful passage of nine resolutions, including the adoption of financial statements, director re-elections, and the appointment of Shipley's LLP as company auditor. These approvals signal strong shareholder confidence in the board's governance and strategic vision.